Stocks · News reference
EVX-05 is an off-the-shelf therapeutic glioblastoma (brain cancer) vaccine designed based on patient tumor samples. It targets novel conserved antigens identified using Evaxion’s AI-Immunology™ platformGlioblastoma is
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
On Thursday, Evaxion Biotech (NASDAQ:EVAX) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.31) by 96.77 percent. This is a 50 percent increase over losses of $(0.02) per share from the
Webull Corp (NASDAQ: BULL) rose sharply in pre-market trading after reporting better-than-expected Q2 results. Revenue of $198.83M beat estimates, while adjusted EPS of $0.05 also beat.
Gainers BioVie (NASDAQ:BIVI) stock increased by 15.7% to $1.55 during Wednesday's after-market session. The market value of their outstanding shares is at $7.2 million. The company's, Q4 earnings came out 4